Novartis Says Top Drugs Should Fuel Sales Growth Through 2026_老虎社区_美港股上老虎

Novartis Says Top Drugs Should Fuel Sales Growth Through 2026

Marketwatch2021-12-02

Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

JaxW
·2021-12-02
Please like and comment 🙏 Thanks
回复
7
举报
收起
- 乐乐兄弟:
  👍
  2021-12-02
  回复
  举报
- WBT13:
  ok
  2021-12-02
  回复
  举报
- cgoh:
  👍🏼👍🏼
  2021-12-02
  回复
  举报
查看更多 1 条评论
SebZz
·2021-12-02
Nice
回复
3
举报
Fionfion82
·2021-12-02
Like
回复
7
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1159695915?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-02 15:15","share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","id":"1159695915","market":"us","top_or_hot":-1,"title":"Novartis Says Top Drugs Should Fuel Sales Growth Through 2026","media":"Marketwatch","content":"<div>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while...</p>\n\n<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">网页链接</a>\n\n</div>\n","source":"market_watch","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Top Drugs Should Fuel Sales Growth Through 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Top Drugs Should Fuel Sales Growth Through 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 15:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while...</p>\n\n<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click","article_id":"1159695915","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159695915","pubTimestamp":1638429346,"columns":[],"sourceInfo":{"source_id":"market_watch","name":"华尔街大事件"},"weMediaInfo":null,"summary":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华"},"translate_title":"诺华称顶级药物将推动销售增长至2026年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.\nThe Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.\n\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.\nNovartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":603567806,"gmtCreate":1638429695202,"gmtModify":1638429695546,"author":{"id":"3582635042920976","authorId":"3582635042920976","name":"JaxW","avatar":"https://static.tigerbbs.com/e387971df14a5a7a9d52e133338baf77","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582635042920976","authorIdStr":"3582635042920976"},"htmlText":"Please like and comment 🙏 Thanks&nbsp;","listText":"Please like and comment 🙏 Thanks&nbsp;","text":"Please like and comment 🙏 Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/603567806","repostId":1159695915,"repostType":4,"repost":{"id":"1159695915","kind":"news","pubTimestamp":1638429346,"share":"https://www.laohu8.com/m/news/1159695915?lang=&edition=full","pubTime":"2021-12-02 15:15","market":"us","language":"en","title":"Novartis Says Top Drugs Should Fuel Sales Growth Through 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1159695915","media":"Marketwatch","summary":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp","content":"<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p>\n<p>The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p>\n<p>\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p>\n<p>Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Top Drugs Should Fuel Sales Growth Through 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Top Drugs Should Fuel Sales Growth Through 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 15:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while...</p>\n\n<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1159695915","content_text":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.\nThe Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.\n\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.\nNovartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6812402,"gmtCreate":1638431966058,"gmtModify":1638431966150,"authorId":3565093231884966,"author":{"id":3565093231884966,"idStr":"3565093231884966","authorId":3565093231884966,"name":"乐乐兄弟","avatar":"https://static.tigerbbs.com/eb090d0ef806d1ab6ea260cffcde7569","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603567806,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":6812244,"gmtCreate":1638430950125,"gmtModify":1638430950229,"authorId":3573351657200487,"author":{"id":3573351657200487,"idStr":"3573351657200487","authorId":3573351657200487,"name":"WBT13","avatar":"https://static.tigerbbs.com/c32eff74d0ce173f7e10df861c0ee416","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603567806,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":6812224,"gmtCreate":1638430832645,"gmtModify":1638430832680,"authorId":4087794564530700,"author":{"id":4087794564530700,"idStr":"4087794564530700","authorId":4087794564530700,"name":"cgoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603567806,"type":1,"supId":0,"prevId":0,"content":"👍🏼👍🏼","text":"👍🏼👍🏼","html":"👍🏼👍🏼"},{"id":6812145,"gmtCreate":1638430283567,"gmtModify":1638430283600,"authorId":3586686862858996,"author":{"id":3586686862858996,"idStr":"3586686862858996","authorId":3586686862858996,"name":"Wz_daebak","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603567806,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":603567349,"gmtCreate":1638429661733,"gmtModify":1638429661852,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603567349","repostId":1159695915,"repostType":4,"repost":{"id":"1159695915","kind":"news","pubTimestamp":1638429346,"share":"https://www.laohu8.com/m/news/1159695915?lang=&edition=full","pubTime":"2021-12-02 15:15","market":"us","language":"en","title":"Novartis Says Top Drugs Should Fuel Sales Growth Through 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1159695915","media":"Marketwatch","summary":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp","content":"<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p>\n<p>The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p>\n<p>\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p>\n<p>Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Top Drugs Should Fuel Sales Growth Through 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Top Drugs Should Fuel Sales Growth Through 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 15:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while...</p>\n\n<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1159695915","content_text":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.\nThe Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.\n\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.\nNovartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603564561,"gmtCreate":1638429578454,"gmtModify":1638429579857,"author":{"id":"3567652695695694","authorId":"3567652695695694","name":"Fionfion82","avatar":"https://static.tigerbbs.com/22ca6345985b52ec868cac92aafafdc1","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3567652695695694","authorIdStr":"3567652695695694"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603564561","repostId":1159695915,"repostType":4,"repost":{"id":"1159695915","kind":"news","pubTimestamp":1638429346,"share":"https://www.laohu8.com/m/news/1159695915?lang=&edition=full","pubTime":"2021-12-02 15:15","market":"us","language":"en","title":"Novartis Says Top Drugs Should Fuel Sales Growth Through 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1159695915","media":"Marketwatch","summary":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp","content":"<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p>\n<p>The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p>\n<p>\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p>\n<p>Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Top Drugs Should Fuel Sales Growth Through 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Top Drugs Should Fuel Sales Growth Through 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 15:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while...</p>\n\n<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1159695915","content_text":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.\nThe Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.\n\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.\nNovartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":20,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}